Skip to main
TVGN
TVGN logo

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings Inc. boasts a promising position in the clinical-stage immunotherapy sector, with its advanced platform technology demonstrating potential applications beyond infectious diseases, including solid tumors and autoimmune disorders, thereby significantly expanding its total addressable market. The company's rapid transition from discovery to clinical application within 18 months highlights its operational efficiency and capability to translate scientific advancements into viable therapies. Additionally, the innovative TVGN 489 product offers vital support for cancer patients infected with SARS-CoV-2, facilitating uninterrupted oncologic care, which underscores the therapeutic value of Tevogen's offerings in critical healthcare scenarios.

Bears say

Tevogen Bio Holdings faces a challenging environment as traditional antiviral strategies are proving less effective among vulnerable populations, which may lead to delays in critical cancer treatments and adversely affect therapeutic success rates. The company's focus on utilizing preserved targets amid the pandemic is problematic, as existing therapies targeting rapidly mutating viral proteins may experience efficacy decline, presenting potential risks to their pipeline. Additionally, while Tevogen claims manufacturing efficiencies over traditional CAR-T methods, delays in treatment for patients, particularly in hematology-oncology and severe rheumatological cases, could undermine their overall market potential and patient outcomes.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Jun 22, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.